Neuren Pharmaceuticals (ASX:NEU) has received Fast Track designation from the US Food and Drug Administration for its investigational therapy NNZ-2591 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder with no approved therapies. …
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 Australian BiotechLatest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News